Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:31 PM ET 10-Q
Financial Results GameSquare Holdings, Inc. GAME

GameSquare Holdings Q3 2026 Results: Turns Profitable, Net Income $10.1M

GameSquare Holdings reported a significant revenue increase to $52.0 million for the nine months ended September 30, 2026, compared to $26.0 million in the prior year period. Despite this growth, the company realized a net loss of $18.3 million, driven by higher operating expenses and a substantial realized loss on digital assets and ETH fund investments.

Key figure
Net income $10.1M
4:31 PM ET 10-Q
Financial Results Oncotelic Therapeutics, Inc. OTLC

Oncotelic Therapeutics Q3 2026 Results: Net Loss of $1.11M, Loss Widens

Oncotelic Therapeutics reported a net loss of $2.92 million for the nine months ended September 30, 2026, compared to a loss of $1.07 million in the prior year period. The company's balance sheet is dominated by a $388 million investment in GMP Bio at fair value, while it continues to manage significant debt obligations and a working capital deficit.

Key figure
Net loss $1.11M
4:31 PM ET 10-Q
Financial Results Safe Pro Group Inc. SPAI

Safe Pro Group Q3 2026 Results: Net Loss of $1.54M, Loss Narrows

Safe Pro Group Inc. reported a significant revenue increase to $5.23 million for the nine months ended September 30, 2026, compared to $0.38 million in the prior year. Despite this growth, the company recorded a net loss of $7.51 million, driven by high operating expenses including $5.65 million in salaries and $2.34 million in professional fees.

Key figure
Net loss $1.54M
4:31 PM ET 10-Q
Financial Results Seafarer Exploration Corp SFRX

Seafarer Exploration Q3 2026 Results: Net Loss of $1.08M, Loss Widens

Seafarer Exploration Corp. reported a net loss of $2,367,325 for the nine months ended September 30, 2026, compared to a loss of $2,055,690 in the prior year period. The company remains in a development stage with zero revenue and a total stockholders' deficit of $3,632,689 as of the reporting date.

Key figure
Net loss $1.08M
4:31 PM ET 10-Q
Financial Results Roadzen Inc. RDZN

Roadzen Q2 2026 Results: Net Loss of $4.08M, Loss Widens

Roadzen Inc. reported a revenue increase to $33.8 million for the six months ended September 30, 2026, compared to $24.5 million in the prior year. However, the company experienced a net loss of $13.9 million for the period, driven by increased interest expenses and fair value losses on financial instruments. The company remains in a total shareholders' deficit of $36.5 million as of September 30, 2026.

Key figure
Net loss $4.08M
4:31 PM ET 10-Q
Financial Results D-Wave Quantum Inc. QBTS

D-Wave Quantum Q3 2026 Results: Net Loss of $48.2M, Loss Narrows

D-Wave Quantum Inc. reported a net loss of $48.2 million for the third quarter of 2026, an improvement from the $140.0 million loss in the prior year period, primarily due to the absence of warrant liability fair value changes. While quarterly revenue grew to $4.5 million, year-to-date revenue declined significantly to $10.4 million compared to $21.8 million in 2025, alongside a substantial increase in research and development expenses.

Key figure
Net loss $48.2M
4:30 PM ET 10-Q
Financial Results PetVivo Holdings, Inc. PETV

PetVivo Holdings Q2 2026 Results: Net Loss of $1.95M, Loss Narrows

PetVivo Holdings reported a net loss of $3,560,419 for the six months ended September 30, 2026, compared to $4,555,587 in the prior year period. Revenues decreased slightly to $550,377, while the company experienced a significant reduction in cash to $16,287 and a total stockholders' deficit of $159,093.

Key figure
Net loss $1.95M
4:30 PM ET 10-Q
Financial Results Starfighters Space, Inc. FJET

Starfighters Space Q3 2026 Results: Net Loss of $4.58M, Loss Widens

Starfighters Space, Inc. reported a net loss of $20.3 million for the nine months ended September 30, 2026, significantly higher than the $7.0 million loss in the prior year period, driven by a $5.15 million impairment of aircraft deposits and increased SG&A expenses. The company raised $17.5 million through PIPE financing but faces substantial doubt about its ability to continue as a going concern due to historical losses and restricted bank accounts from ongoing litigation.

Key figure
Net loss $4.58M
4:30 PM ET 10-Q
Financial Results Stewards, Inc. SWRD

Stewards Q3 2026 Results: Net Loss of $19.4M, Loss Widens

Stewards, Inc. reported total revenues of $10.7 million for the nine months ended September 30, 2026, a decrease from $12.0 million in the prior year period. The company experienced a significant net loss of $32.3 million during this period, driven by increased operating expenses and a $7.1 million change in the fair value of warrant liabilities.

Key figure
Net loss $19.4M
4:30 PM ET 10-Q
Financial Results Archimedes Tech SPAC Partners III Co. ARCI

Archimedes Tech SPAC Partners III Q3 2026 Results: Turns Profitable, Net Income $2.34M

Archimedes Tech SPAC Partners III Co. reported a net income of $6.20 million for the nine months ended September 30, 2026, primarily driven by $6.82 million in interest earned on the Trust Account. As a shell company, it holds $282.82 million in a Trust Account to fund a future business combination and reported a shareholders' deficit of $8.77 million due to the accretion of ordinary shares to redemption value.

Key figure
Net income $2.34M
4:30 PM ET 8-K
Financial Results Bally's Corp BALY

Bally's Financial Results

Bally's Corp reported Q3 2026 consolidated revenue of $807.6 million, a 21.7% increase year-over-year, driven by strong growth in its Intralot B2C and North America Interactive segments. The company also highlighted the closing of a $400 million term loan for its Bronx project and confirmed that construction of its permanent Chicago casino remains on schedule for a spring 2027 opening.

“We delivered another solid quarter, with consolidated revenue up 21.7% year over year. Revenue growth was led by Bally’s Intralot B2C which rose 22.8% and North America Interactive which increased 25.6% while Casinos & Resorts revenue rose 3.2% reflecting strong regional gaming performance.”

Robeson Reeves, Bally’s Chief Executive Officer

“Bally’s will meet and likely exceed the $1.34 billion minimum capital commitment required under our agreement with the City of Chicago, we have the capital resources necessary to do so and are very excited to bring Chicago its first and only full service gaming and entertainment resort.”

Robeson Reeves, Bally’s Chief Executive Officer
4:30 PM ET 10-Q
Financial Results VenHub Global, Inc. VHUB

VenHub Global Q3 2026 Results: Net Loss of $11M, Loss Narrows

VenHub Global, Inc. reported a net loss of $38.1 million for the nine months ended September 30, 2026, compared to a $49.2 million loss in the prior year period. Total revenue decreased to $244,245 from $808,972 year-over-year, primarily due to the absence of store sales, while the company continues to manage significant operating expenses and a stockholders' deficit of $5.0 million.

Key figure
Net loss $11M
4:30 PM ET 10-Q
Financial Results Teamshares Inc TMS

Teamshares Q3 2026 Results: Net Loss of $9.4M, Loss Widens

Teamshares Inc. reported total revenue of $417.6 million for the nine months ended September 30, 2026, a 21% increase year-over-year, though it recorded a net loss of $22.6 million. The company significantly strengthened its balance sheet through a merger and PIPE financing, as well as the issuance of $225 million in perpetual non-convertible preferred stock.

Key figure
Net loss $9.4M
4:30 PM ET 10-Q
Financial Results Stem, Inc. STEM ▶ Call

Stem Q3 2026 Results: Net Loss of $14.6M, Loss Narrows

Stem, Inc. reported total revenue of $36.7 million for the third quarter of 2026, a slight decrease from $38.2 million in the prior year period. The company saw a significant reduction in net loss to $14.6 million compared to a $23.8 million loss in Q3 2025, driven by improved gross margins and lower operating expenses.

Key figure
Net loss $14.6M
4:30 PM ET 10-Q
Financial Results Flash Sports & Media Holdings, Inc. FLZH

Flash Sports & Media Holdings Q3 2026 Results: Net Loss of $6.81M, Loss Widens

Flash Sports & Media Holdings, Inc. completed a pivot from agriculture to sports and media following a merger, resulting in a significant increase in total assets to $256.5 million. Despite generating $8.17 million in revenue for the nine months ended September 30, 2026, the company reported a net loss of $19.4 million and expressed substantial doubt about its ability to continue as a going concern.

Key figure
Net loss $6.81M
4:30 PM ET 10-Q
Financial Results Dawson Geophysical Co DWSN

Dawson Geophysical Q3 2026 Results: Net Loss of $5.2M, Loss Widens

Dawson Geophysical reported a net loss of $946,000 for the nine months ended September 30, 2026, an improvement from the $2,510,000 loss in the prior year period. Total operating revenues increased significantly to $66,029,000 from $48,675,000, driven by higher fee revenue, though the company experienced a substantial net loss of $5,167,000 in the third quarter of 2026.

Key figure
Net loss $5.2M
4:30 PM ET 10-Q
Financial Results Aeon Biopharma, Inc. AEON

Aeon Biopharma Q3 2026 Results: Turns Profitable, Net Income $2.46M

AEON Biopharma reported a net loss of $10.5 million for the nine months ended September 30, 2026, compared to a $2.1 million loss in the prior year period. The company significantly strengthened its balance sheet through public offerings and PIPE financing, increasing cash and cash equivalents to $11.4 million and reducing total liabilities from $60.6 million to $11.7 million.

Key figure
Net income $2.46M
4:30 PM ET 10-Q
Financial Results Oric Pharmaceuticals, Inc. ORIC

Oric Pharmaceuticals Q3 2026 Results: Net Loss of $48.1M, Loss Widens

For the nine months ended September 30, 2026, ORIC Pharmaceuticals reported a net loss of $125.3 million, an increase from the $99.0 million loss in the prior year period, primarily driven by higher research and development expenses. As of September 30, 2026, the company maintained a strong liquidity position with $345.4 million in cash, cash equivalents, and investments.

Key figure
Net loss $48.1M
4:30 PM ET 10-K
Financial Results Twist Bioscience Corp TWST

Twist Bioscience FY 2026 Results: Net Loss of $130M, Loss Widens

Twist Bioscience reported net proceeds of approximately $327.7 million from an August 2026 public offering and $97.1 million from an at-the-market program. Despite these capital raises, the company anticipates continued net losses and negative free cash flows for the near future while expanding international operations, which accounted for 41% of revenue in fiscal 2026.

Key figure
Net loss $130M
4:30 PM ET 8-K
Financial Results T Stamp Inc IDAI

T Stamp Financial Results

T Stamp Inc. (Trust Stamp) reported financial results for the nine months ended September 30, 2026, featuring a 28% increase in net revenue to $2.85 million. The company noted that revenue growth is significantly outpacing the growth in cash expenses, driven by work with an S&P 500 bank and a multinational telecommunications corporation. Trust Stamp also highlighted a maturing revenue pipeline with a conservative FY 2027 projection of $8.17 million in booked revenue.

Term
9 months
4:29 PM ET 8-K
Financial Results Vulcan Infrastructure & Power Inc. VIP

Vulcan Infrastructure & Power Financial Results

Vulcan Infrastructure and Power reported Q3 2026 financial results, highlighting a strategic transition toward AI and high-performance computing (HPC) infrastructure. The company strengthened its balance sheet by completing a $39.3 million strategic investment and redeeming its 2026 Senior Notes, effectively eliminating its 2026 debt maturity.

“During the third quarter and subsequent to quarter-end, we completed three important steps in Vulcan’s transition. In September, we closed a $39.3 million strategic investment from Atlas Holdings, Machine Investment Group, Conversant Capital, and other investors, and in October we completed the full redemption of our 8.50% Senior Notes due 2026 (the “2026 Notes”).”

Jordan Kovler, CEO

“Our immediate focus is on advancing our owned sites at Dresden and Columbus through predevelopment work and with AI/HPC customers. Our objective is to translate the power and infrastructure value of these assets into contracted, predictable, long-duration cash flows.”

Jordan Kovler, CEO
4:29 PM ET 8-K
Financial Results Oric Pharmaceuticals, Inc. ORIC

Oric Pharmaceuticals Financial Results

ORIC Pharmaceuticals reported third quarter 2026 financial results and provided updates on its late-stage oncology portfolio, including the initiation of the Himalayas-1 Phase 3 trial for rinzimetostat in prostate cancer. The company ended the quarter with $345 million in cash and investments, which is expected to fund operations into the second half of 2028.

“Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC.”

Jacob M. Chacko, M.D., president and chief executive officer

“With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer.”

Jacob M. Chacko, M.D., president and chief executive officer
4:29 PM ET 8-K
Financial Results Enanta Pharmaceuticals Inc ENTA

Enanta Pharmaceuticals Financial Results

Enanta Pharmaceuticals reported fiscal fourth quarter 2026 revenue of $12.9 million and a net loss of $28.3 million, driven by royalty revenue from AbbVie's HCV regimen. The company highlighted clinical progress in its RSV and immunology pipelines, including the completion of enrollment for its Phase 2b LOTUS trial. Enanta also announced the planned retirement of CEO Jay R. Luly by February 2027.

Counterparty
AbbVie

“During fiscal 2026 we made significant progress across our virology and immunology portfolios. In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients, with topline data expected in the first quarter of 2027. We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027.”

Jay R. Luly, Ph.D., President and Chief Executive Officer

“In parallel, we are advancing a growing immunology portfolio focused on developing best-in-class oral medicines that have the potential to raise the standard of care across multiple immune-mediated diseases. We expect to complete dosing in the EDP-978 Phase 1 trial by year-end 2026 and now plan to report data in the first quarter of 2027.”

Jay R. Luly, Ph.D., President and Chief Executive Officer
4:29 PM ET 8-K
Financial Results Omeros Corp OMER

Omeros Financial Results

Omeros Corporation reported Q3 2026 financial results, highlighted by a 26% sequential increase in net revenue for YARTEMLEA to $35.9 million. The company reported a GAAP net loss of $57.4 million, primarily driven by a $62.0 million non-cash mark-to-market adjustment on convertible notes, while achieving positive operating cash flow of $13.3 million.

Term
Q3 2026

“YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow. As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA. That momentum has continued into the fourth quarter, with YARTEMLEA revenues continuing to grow.”

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer
4:29 PM ET 8-K
Financial Results Lifeloc Technologies, Inc LCTC

Lifeloc Technologies Financial Results

Lifeloc Technologies reported Q3 2026 net revenue of $2.522 million, a 12% increase year-over-year, and a narrowed net loss of $85 thousand. The company highlighted margin improvements from price increases and continued heavy R&D investment in its SpinDetect drug analyzer platform, which is entering beta testing.

Term
Q3 2026
4:29 PM ET 8-K
Financial Results Getty Images Holdings, Inc. GETYQ

Getty Images Holdings Financial Results

Getty Images reported Q3 2026 revenue of $234.0 million, a 2.5% year-over-year decrease, and a net loss of $564.5 million primarily driven by $563.2 million in non-cash impairment charges. The company also announced it has initiated a prepackaged Chapter 11 restructuring process to transition to a privately held company with the support of the Getty family and Koch Equity Development.

Term
Q3 2026

“As recently announced, we initiated a financial restructuring to significantly strengthen our financial foundation and accelerate our ability to invest for growth with the support of the Getty family, Koch Equity Development and our lenders as a privately held company.”

Craig Peters, Chief Executive Officer of Getty Images

“We continue to service our customers through the world's best authentic visual content and coverage. Importantly, we remain focused on what we do best, which is helping our customers engage their audiences.”

Craig Peters, Chief Executive Officer of Getty Images
4:29 PM ET 8-K
Financial Results Luvu Brands, Inc. LUVU

Luvu Brands Financial Results

Luvu Brands reported first quarter fiscal 2027 net sales growth of 10% to $6.8 million, driven by strength in wholesale and international channels. Despite the revenue growth, the company reported a net loss of $365,000 as higher freight and manufacturing labor costs compressed gross margins to 26.2%.

Term
Q1 2027

“We opened fiscal 2027 with double-digit top-line growth, led by continued strength in our Wholesale channel, particularly adult retailers and international customers, and by better conversion on our Liberator website following its move to the Shopify platform. We are adding distribution points at home and abroad, and we are encouraged by the momentum in both our Direct and Wholesale channels.”

Louis Friedman, Founder, Chief Executive Officer of Luvu Brands
4:29 PM ET 8-K
Financial Results Roadzen Inc. RDZN

Roadzen Financial Results

Roadzen reported record quarterly revenue of $17.6 million for Q2 fiscal 2027, representing 28.6% year-over-year growth. The company achieved its first-ever positive Adjusted EBITDA quarter and narrowed its operating loss by 24% as it targets a $100 million annualized revenue run rate by fiscal year-end.

Term
Q2 2027

“This is the quarter we have been building toward for two years. Roadzen generated positive Adjusted EBITDA for the first time in its history, on record revenue of $17.6 million, our third record quarter in a row, after nine consecutive quarters of disciplined improvement.”

Rohan Malhotra, Founder and CEO of Roadzen

“We process more than three million claims a year, our driver-safety AI runs across billions of miles of real-world driving, and our AI agents now do work inside inspection, claims and repair that used to take weeks, and that is the engine behind these numbers.”

Rohan Malhotra, Founder and CEO of Roadzen
4:29 PM ET 8-K
Financial Results SharonAI Holdings Inc. SHAZ

SharonAI Holdings Financial Results

Roadzen reported record revenue of $17.6 million for the second fiscal quarter, up 28.6% year-over-year, and achieved its first positive Adjusted EBITDA quarter in company history. The company also announced a $10 million equity financing for its India subsidiary at a $300 million post-money valuation and reaffirmed its target to exit fiscal 2027 at a $100 million-plus annualized revenue run rate.

Term
Q2 2027

“This is the quarter we have been building toward for two years. Roadzen generated positive Adjusted EBITDA for the first time in its history, on record revenue of $17.6 million, our third record quarter in a row, after nine consecutive quarters of disciplined improvement.”

Rohan Malhotra, Founder and CEO of Roadzen

“We process more than three million claims a year, our driver-safety AI runs across billions of miles of real-world driving, and our AI agents now do work inside inspection, claims and repair that used to take weeks, and that is the engine behind these numbers.”

Rohan Malhotra, Founder and CEO of Roadzen
4:29 PM ET 8-K
Financial Results Infleqtion, Inc. INFQ

Infleqtion Financial Results

Infleqtion reported record Q3 2026 revenue of $9.1 million, a 25% year-over-year increase, driven by its neutral atom quantum computing and sensing business. The company achieved a major technical milestone by demonstrating 30 logical qubits and maintained its full-year 2026 revenue guidance of at least $45.1 million.

Term
Q3 2026

“We are building Infleqtion to lead in utility-scale quantum computing, and this quarter’s progress strengthens our confidence in that ambition. Delivering 30 logical qubits is an important step on our technology roadmap. Alongside that progress, growth in our backlog and remaining performance obligations gives us confidence in a strong 2027 across computing and sensing, with computing becoming a meaningfully larger part of our business.”

Matt Kinsella, CEO of Infleqtion

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.